Amneal Pharmaceuticals (AMRX) Gross Margin (2017 - 2026)

Amneal Pharmaceuticals' Gross Margin history runs 10 years deep, the most recent figure standing at 44.31% for Q1 2026.

• On a quarterly basis, Gross Margin rose 751.0% year-over-year to 44.31% in Q1 2026; TTM through Mar 2026 was 38.66%, a 197.0% increase from a year earlier, with the FY2025 full-year figure at 36.88%, up 36.0% from the prior year.
• Gross Margin climbed to 44.31% in Q1 2026 per AMRX's latest filing, from 36.5% in the prior quarter.
• Across five years, Gross Margin topped out at 44.31% in Q1 2026 and bottomed at 13.61% in Q4 2022.
• The 5-year median for Gross Margin is 35.98% (2024), against an average of 33.41%.
• Across the five-year window, Gross Margin plunged 4460 bps in 2022 and jumped 4438 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 13.61% in 2022, then jumped by 326 bps to 30.77% in 2023, then grew by 17 bps to 35.98% in 2024, then rose by 1 bps to 36.5% in 2025, then gained by 21 bps to 44.31% in 2026.
• Per Business Quant, the three latest AMRX Gross Margin figures stand at 44.31% (Q1 2026), 36.5% (Q4 2025), and 34.92% (Q3 2025).